Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Allos to complete merger with AMAG Pharmaceuticals

Allos to complete merger with AMAG Pharmaceuticals

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Study identifies gene mutation responsible for higher frequency of Italian CDA II

Study identifies gene mutation responsible for higher frequency of Italian CDA II

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Researchers identify new enzyme function that may protect against anemia

Researchers identify new enzyme function that may protect against anemia

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Patients with chronic hepatitis C less likely to take medications over time

Patients with chronic hepatitis C less likely to take medications over time

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Burundi makes significant progress against NTDs

Burundi makes significant progress against NTDs

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Drug combo for breast cancer in post-menopausal women shows promise

Drug combo for breast cancer in post-menopausal women shows promise

Sodium Stibogluconate & Paromomycin combination treatment for Kala azar

Sodium Stibogluconate & Paromomycin combination treatment for Kala azar

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.